Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies
Clinical Lymphoma, Myeloma and Leukemia · Published 2026-05-18 · DOI 10.1016/j.clml.2026.05.002
Authors (11)
David Martínez-Campuzano, Clara Sopeña, María José Moreno, María Sánchez, Adriana Gascón, Pablo Lorente, Mario Montagud, Jaime Martí, Silvina Ríos, Mario Arnao, Javier de la Rubia
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Martínez-Campuzano, D., Sopeña, C., Moreno, M., et al. (2026). Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. Clinical Lymphoma, Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.05.002
Related articles
- KMT2A-Partial Tandem Duplication associates with leukemia transformation in myelodysplastic syndrome · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Bispecific Antibody Therapy With Elranatamab for Refractory Waldenström Macroglobulinemia: A Case Report · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Treatment modalities and the impact of granulocyte colony-stimulating factor in AML patients treated with venetoclax and azacitidine: A DATAML registry study · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Real-World Treatment Patterns and Outcomes for Patients With Relapsed/Refractory Multiple Myeloma and Prior Exposure to Lenalidomide and Proteasome Inhibitors in the United States · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential/Clonal Cytopenia of Uncertain Significance · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal
- SOHO State of the Art Updates and NextQuestions | Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic Leukemia · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Same journal